Corcept Therapeutics reported Phase 3 data showing that relacorilant added to chemotherapy reduced risk of death by 35% in platinum‑resistant ovarian cancer, meeting a prespecified overall survival endpoint. The readout followed earlier progression‑free survival gains and gives Corcept a data package to support its upcoming regulatory interactions and potential U.S. filing. Corcept and market analysts project sizable commercial potential if approved; one note estimated peak sales in the multi‑billion dollar range. The company still faces a pending PDUFA timeline and prior regulatory setbacks in other indications, so final labeling and payer positioning will be pivotal.